Efficacy and Safety of Delgocitinib and Its Impact on Patient's Perspective for Moderate-to-severe Chronic Hand Eczema in Adults: A 16-week Real-world Prospective Multicentre Study.

Authors

Elena Pezzolo, Raul Armando Luyo Saboya, Michela Ortoncelli, Simone Ribero, Federica Gelato, Marco Galluzzo, Marina Talamonti, Edoardo Mortato, Antonio Costanzo, Luigi Gargiulo, Alessandra Narcisi, Matteo Bianco, Carlotta Gurioli, Gionathan Orioni, Camilla Loi, Niccolò Gori, Ketty Peris, Elena Ippoliti, Giampiero Girolomoni, Martina Maurelli, Maria Esposito, Sara Triolo, Caterina Foti, Giorgia Sbarra, Ersilia Tolino, Nevena Skroza, Andrea Carugno, Nicola Zerbinati, Anna Balato, Eugenia Veronica Di Brizzi, Martina Burlando, Vito Di Lernia, Pietro Morrone, Emiliano Antiga, Maria Concetta Fargnoli, Filomena Russo, Francesca Caroppo, Laura Fagotto, Piergiacomo Calzavara-Pinton, Stefano Bighetti, Mariateresa Rossi

Published in

Acta dermato-venereologica. Volume 106. Oct 07, 2026. Epub Oct 07, 2026.

Abstract

Delgocitinib is a pan-Janus kinase inhibitor approved for moderate-to-severe chronic hand eczema (CHE) in adults. However, real-world evidence remains limited. We prospectively evaluated 149 adult patients (mean age: 46.4 years; 60.4 % female) treated with delgocitinib for chronic hand eczema across 20 Italian dermatology centres between May and November 2025, with a four-month follow-up. Two-thirds of patients were non-occupationally exposed, and>80% had vesicular or atopic chronic hand eczema. At week 4, Physician Global Assessment (PGA)-chronic hand eczema 0/1 and Hand Eczema Severity Index (HECSI)-75 were achieved in 42.3% and 43.8% of patients, increasing significantly to 74.3% and 88.0% at week 16. Pruritus and pain Numerical Rating Scale (NRS) 0/1 were reported in 43.8% and 52.3% of patients at week 4, rising significantly to 74.4% and 86.5% at week 16. Hand Eczema Symptom Diary-Patient Global Impression of Severity (HESD PGI-S) 0/1 increased from 45.6% to 76.6%. Non-occupationally exposed patients showed significantly higher early response rates than occupationally exposed, with attenuation of differences by week 16. HECSI-75 responses were consistent across chronic hand eczema subtypes, particularly vesicular (94.0%) and atopic (90.0%). Treatment was well tolerated, with rare and no severe adverse events reported. These findings support delgocitinib as a rapid, effective and safe treatment option for chronic hand eczema.

PMID:
42839349
Bibliographic data and abstract were imported from PubMed on 07 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.